申请人:Aventis Pharmaceuticals Inc.
公开号:US07576109B2
公开(公告)日:2009-08-18
The present invention is directed to 1,3,4-oxadiazolones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein.
The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization.
本发明涉及1,3,4-噁二唑酮,化合物I的药学上可接受的盐、立体异构体、互变异构体或其溶剂。新颖的化合物包括式I中的基团如本文所定义。本发明的化合物是PPARδ调节剂,因此可用作药物制剂,特别是用于治疗脱髓鞘疾病和脂肪酸代谢和葡萄糖利用障碍。